The inaugural Genetic Vaccine Development for Infectious Diseases Summit will unite 100+ leading biotech & pharma companies, and pioneering academics and NPOs, to better understand how these powerful new tools can contribute to global public health.
With a focus on mRNA, DNA, and engineered viral vector-based vaccines, this niche 3-day agenda has been specifically designed to help industry experts to overcome immunogenicity challenges, define clinically meaningful endpoints and forge powerful industry collaborations to prevent and treat infectious diseases.
We'll be covering clinical trial updates for pregnant women on Covid-19 candidates, long term correlates of protection, and also unpublished data on gene-based vaccines for a wide range of infectious diseases, including HIV, Ebola, Lassa Fever, Influenza, Zika, MERS, and Covid-19.
With 30+ confirmed speakers from Pfizer, AstraZeneca, BioNTech, Moderna, CureVac, CEPI, INOVIO, and Janssen.
Ask for a Free trial and get access to the latest stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.